Your session is about to expire
← Back to Search
ZEN003694 + Nivolumab/Ipilimumab for Cancer
Study Summary
This trial is testing a new drug, ZEN003694, to see if it's effective and safe when given with nivolumab with or without ipilimumab to treat patients with solid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
Are investigators currently accepting participants in this experiment?
"Affirmative. Clinicaltrials.gov's records show that this trial, posted on October 6th 2021, is still actively searching for participants. The study seeks to enrol 66 patients from 7 distinct medical sites."
What maladies can be addressed through the utilization of BET Bromodomain Inhibitor ZEN-3694?
"ZEN-3694, a BET Bromodomain inhibitor, is an effective therapy for those previously treated with antiangiogenic agents and can be used to treat malignancies such as unresectable melanoma or squamous cell carcinoma."
How many venues are responsible for overseeing the progress of this research project?
"As per the data on clinicaltrials.gov, this trial is recruiting patients at Montefiore Medical Center-Einstein Campus in Bronx, New york, National Cancer Institute Developmental Therapeutics Clinic in Bethesda, Maryland, and National Institutes of Health Clinical Center along with a further 7 sites."
How many participants are engaging in this experiment?
"Affirmative. The details on clinicaltrials.gov verify that this experiment, which was initially published on October 6th 2021, is still enlisting volunteers. Approximately 66 patients are required from 7 distinct sites of study."
Has the Food and Drug Administration given their seal of approval to BET Bromodomain Inhibitor ZEN-3694?
"The safety rating of BET Bromodomain Inhibitor ZEN-3694 was judged to be a 1 as this is early stage research, with sparse evidence regarding its efficacy and limited analysis on the drug's security."
To what extent has ZEN-3694 been explored as a BET Bromodomain Inhibitor through prior clinical experiments?
"Currently, there are 764 studies related to the BET Bromodomain Inhibitor ZEN-3694 in progress. Of those active trials, 86 have moved into stage 3 of testing. The majority of these investigations are being conducted within Pittsburgh but they span 42751 locations around the world."
Share this study with friends
Copy Link
Messenger